CN111436597A - Lipid chain peptide and production process thereof - Google Patents

Lipid chain peptide and production process thereof Download PDF

Info

Publication number
CN111436597A
CN111436597A CN202010252471.7A CN202010252471A CN111436597A CN 111436597 A CN111436597 A CN 111436597A CN 202010252471 A CN202010252471 A CN 202010252471A CN 111436597 A CN111436597 A CN 111436597A
Authority
CN
China
Prior art keywords
weight
parts
mixture
lipopeptide
mixing
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN202010252471.7A
Other languages
Chinese (zh)
Other versions
CN111436597B (en
Inventor
方益胜
石汉平
李增宁
余震
丛明华
李涛
刘新旗
倪锐
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Ruoyuote Medical Food Co ltd
Original Assignee
Shandong Ruoyuote Medical Food Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Ruoyuote Medical Food Co ltd filed Critical Shandong Ruoyuote Medical Food Co ltd
Priority to CN202010252471.7A priority Critical patent/CN111436597B/en
Publication of CN111436597A publication Critical patent/CN111436597A/en
Application granted granted Critical
Publication of CN111436597B publication Critical patent/CN111436597B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/19—Dairy proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/20—Reducing nutritive value; Dietetic products with reduced nutritive value
    • A23L33/21—Addition of substantially indigestible substances, e.g. dietary fibres
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pediatric Medicine (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides the field of food and special food, and particularly relates to a lipid chain peptide and a production process thereof, wherein the lipid chain peptide comprises the following nutrients in parts by weight: 45-55 parts of protein, 20-25 parts of fat, 15-25 parts of carbohydrate, 5-10 parts of dietary fiber, 0.3-0.6 part of sodium, 0.01-0.02 part of vitamin E, 0.1-0.3 part of vitamin C and 0.008-0.012 part of zinc; aiming at the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of the nourishment of a tumor patient, the invention provides the lipid chain peptide element which is reasonably matched with protein, fat, dietary fiber and the like, particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid, realizes the characteristics of quick nutritional absorption, high value and the like, and greatly improves the supply of the patient to the requirements of protein and energy.

Description

Lipid chain peptide and production process thereof
Technical Field
The invention relates to the field of food and special food, in particular to a lipid chain peptide and a production process thereof.
Background
Tumor itself is a wasting disease, patients are commonly suffering from malnutrition, and weight loss is not only a major symptom of tumor patients, but also a cause of worsening prognosis. Patients with non-terminal tumors often have poor disease due to malnutrition, and thus cannot undergo surgery, radiation or chemotherapy, but if they are well nourished, the patients can be prevented or reduced from having poor disease probability by adopting nutrition therapy to a certain extent, so as to improve the disease.
The highest goals of nutrition therapy are to regulate metabolism, control tumors, improve quality of life, and prolong life time, and the basic requirements are to meet more than 70% of energy requirement and 100% of protein requirement of the target requirement of tumor patients.
Disclosure of Invention
In order to solve the problems of insufficient nutritional value, poor effect, insufficient absorption and the like of the nutriment for tumor patients in the prior art, the invention provides the lipid chain peptide element which is reasonably matched with protein, fat, dietary fiber and the like, particularly a high-quality protein matrix consisting of whole protein, short peptide and amino acid is configured, so that the characteristics of quick nutritional absorption, high value and the like are realized, and the supply of the requirements of the patients on the protein and the energy is greatly improved.
The invention is realized by the following technical scheme.
The lipid chain peptide element comprises the following nutrients in parts by weight:
Figure BDA0002435990930000011
preferably, the nutrient comprises the following nutrients in parts by weight:
Figure BDA0002435990930000012
Figure BDA0002435990930000021
preferably, the protein source is one or more of isolated whey protein, short peptides, amino acids, casein, sodium caseinate. The whey protein isolate is used, the purity of the whey protein isolate is 88-95%, the whey protein isolate is processed by the technologies of filtering, drying and the like again on the basis of the concentrated whey protein, the lactose in the whey protein isolate is completely removed, and the whey protein isolate has the characteristic of quick absorption.
Preferably, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
Preferably, the amino acid is one or more of arginine, glutamyl acid and leucine.
Preferably, the fat source is one or more of medium chain triglyceride microcapsule powder, linseed oil microcapsule powder, fish oil microcapsule powder.
Preferably, the source of dietary fibre is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, oligomannose, microcrystalline cellulose.
Preferably, the raw material sources comprise the following components in parts by weight:
Figure BDA0002435990930000022
Figure BDA0002435990930000031
preferably, the feed also comprises an immune nutrient, wherein the content of the immune nutrient is 1.2-7 parts by weight.
Preferably, the source of the immune nutrient is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soybean lecithin, citric acid, zinc gluconate and shiitake mushroom extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
Figure BDA0002435990930000032
preferably, the calcium butyrate also comprises β -hydroxy- β -methyl butyrate, and the content of the calcium butyrate is 1 to 3 parts by weight.
The invention also provides a production process of the lipopeptide hormone, which comprises the following steps:
the method comprises the following steps: weighing 0.02-0.07 part by weight of sucralose, 0.01-0.05 part by weight of disodium 5 '-guanylate, 0.01-0.05 part by weight of disodium 5' -inosinate, 0.08-0.2 part by weight of zinc gluconate, 0.02-0.06 part by weight of vitamin E and 0.15-0.3 part by weight of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of oligomannose, 0.2-0.7 part by weight of mushroom extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter taste masking essence and 0.2-0.7 part by weight of milk essence. Putting the mixture and the first mixture into a three-dimensional mixer for mixing, and sieving the mixture by a 40-mesh sieve to form a second mixture;
weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of β -hydroxy- β -calcium methylbutyrate, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule, and putting the mixture and the second mixture into a three-dimensional mixer for mixing to form a third mixture;
step four: weighing 1-9 parts of inulin, 5-9 parts of collagen peptide, 8-20 parts of linseed oil microcapsule powder and 2-6 parts of arginine. Putting the mixture and the third mixture into a three-dimensional mixer for mixing, and sieving by a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium-chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the fourth mixture and the fourth mixture into a pyramid mixer for mixing to obtain the required lipopeptide element.
Preferably, the mixing frequency of the three-dimensional mixer in step two, step three and step four is 40Hz, and the mixing time is 30min, and wherein the capacity of the three-dimensional mixer in step two is 20L, and the capacity of the three-dimensional mixer in step three and step four is 200L.
Preferably, in step five, the mixing speed of the square cone mixer is 9rpm, the mixing time is 45min, and the capacity is 600L.
Glutamine can enhance intestinal barrier, and can maintain gastrointestinal flora balance and promote nutrient absorption by combining with various dietary fibers (resistant dextrin, inulin, isomaltooligosaccharide, trehalose, oligomannose and microcrystalline cellulose).
The active polysaccharide and the polymer thereof have good pharmacological activity in the aspects of immunoregulation, tumor resistance, inflammation resistance, radiation resistance, cholesterol reduction, blood pressure reduction, thrombus resistance and the like.
Lentinan can induce the generation of immunocompetent cytokines to perform defense and killing effects on tumor cells, and can be combined with other treatment means to relieve the inhibition of operations and chemoradiotherapy on immune functions, increase the chemoradiotherapy tolerance, improve the survival rate and improve the life quality.
Perioperative use of enteral nutrition containing immunomodulatory components (arginine, omega-3 fatty acids and nucleotides) is contemplated for patients undergoing major cervical and abdominal surgery.
The invention has the following beneficial effects:
the lipopeptide preparation system formed by matching a high-quality protein matrix, a fat supply matrix, an immunoregulatory factor, active polysaccharide, an antioxidant and the like is adopted, protein and energy supply is considered, and the aims of maintaining balanced and sufficient absorption of nutrition in a patient are achieved in the aspects of stimulating an mTOR (mammalian target of rapamycin) pathway, synthesizing cholesterol, synthesizing mitochondria, releasing calcium ions in SR, proliferating satellite cells, inhibiting a ubiquitin-proteasome system, inhibiting an autophagy-caspase system and the like.
Detailed Description
The present invention will be described in further detail with reference to examples. It should be understood that the specific embodiments described herein are merely illustrative of the invention and are not intended to limit the invention.
The lipopeptide element comprises the following nutrients in parts by weight:
Figure BDA0002435990930000041
as a preferred embodiment, the following nutrients are included in parts by weight:
Figure BDA0002435990930000051
as a preferred embodiment, the protein source is one or more of isolated whey protein, short peptides and amino acids. The purity of the separated whey protein is 88-95%, and the separated whey protein is processed by the technologies of filtering again, drying and the like on the basis of concentrated whey protein, so that the lactose in the WPC is completely removed, and the WPC has the characteristic of quick absorption.
As a preferred embodiment, the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
As a preferred embodiment, the amino acid is composed of one or more of arginine, glutamyl acid and leucine.
As a preferred embodiment, the fat source is one or more of linseed oil microcapsule powder, fish oil microcapsules and medium chain triglyceride microcapsule powder.
As a preferred embodiment, the dietary fiber source is one or more of resistant dextrin, inulin, isomaltooligosaccharide, trehalose, oligomannose, microcrystalline cellulose.
As a preferred embodiment, the raw material sources comprise the following components in parts by weight:
Figure BDA0002435990930000052
Figure BDA0002435990930000061
as a preferred embodiment, the feed also comprises an immune nutrient, wherein the immune nutrient is contained in 1.2-7 parts by weight.
In a preferred embodiment, the source of the immunonutrients is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soya lecithin, citric acid, zinc gluconate, and shiitake mushroom extract.
Preferably, the immune nutrient comprises the following components in parts by weight:
Figure BDA0002435990930000062
as a preferred embodiment, the calcium butyrate also comprises β -hydroxy- β -methylbutyrate, which is contained in an amount of 1-3 parts by weight.
The invention also provides a production process of the lipopeptide hormone, which comprises the following steps:
the method comprises the following steps: weighing 0.02-0.07 part by weight of sucralose, 0.01-0.05 part by weight of disodium 5 '-guanylate, 0.01-0.05 part by weight of disodium 5' -inosinate, 0.08-0.2 part by weight of zinc gluconate, 0.02-0.06 part by weight of vitamin E and 0.15-0.3 part by weight of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of oligomannose, 0.2-0.7 part by weight of mushroom extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter taste masking essence and 0.2-0.7 part by weight of milk essence. Putting the mixture and the first mixture into a three-dimensional mixer for mixing, and sieving the mixture by a 40-mesh sieve to form a second mixture;
weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of β -hydroxy- β -calcium methylbutyrate, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule, and putting the mixture and the second mixture into a three-dimensional mixer for mixing to form a third mixture;
step four: weighing 1-9 parts of inulin, 5-9 parts of collagen peptide, 8-20 parts of linseed oil microcapsule powder and 2-6 parts of arginine. Putting the mixture and the third mixture into a three-dimensional mixer for mixing, and sieving by a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium-chain triglyceride microcapsule powder and 20-60 parts by weight of isolated whey protein. And putting the fourth mixture and the fourth mixture into a pyramid mixer for mixing to obtain the required lipopeptide element.
As a preferred embodiment, the mixing frequency of the three-dimensional mixer in step two, step three and step four is 40Hz, and the mixing time is 30min, and wherein the capacity of the three-dimensional mixer in step two is 20L, and the capacity of the three-dimensional mixer in step three and step four is 200L.
In a preferred embodiment, in step five, the mixing speed of the square cone mixer is 9rpm, the mixing time is 45min, and the capacity is 600L.
This embodiment further illustrates the beneficial effects of this patent through five specific examples.
TABLE 1 lipopeptide base Material formulation
Figure BDA0002435990930000071
Figure BDA0002435990930000081
The formula of each raw material in the embodiment is shown in table 1, and the production process of the lipopeptide element formed by the five groups of formulas is concretely as follows:
(1) stock preparation
The preparation method comprises the steps of taking isolated whey protein, linseed oil microcapsule powder, medium-chain triglyceride microcapsule powder, collagen peptide, arginine, inulin, fish oil microcapsule, glutamine, β -hydroxy- β -calcium methylbutyrate, leucine, wheat oligopeptide, sea cucumber peptide, mushroom extract, oligomannose, isomaltulose, vitamin C, vitamin E, zinc gluconate, disodium 5 '-guanylate, disodium 5' -inosinate, soybean phospholipid, microcrystalline cellulose, citric acid, bitter taste masking essence, milk essence and sucralose.
(2) Mixing
Weighing sucralose, disodium 5 '-guanylate, disodium 5' -inosinate, zinc gluconate, vitamin E and vitamin C according to the formula ratio, and uniformly mixing to form a first mixture.
Weighing the mannose oligomer, the mushroom extract, the sea cucumber peptide, the bitter taste masking essence and the milk essence according to the formula ratio, putting the weighed materials and the first mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving by a 40-mesh sieve to form a second mixture.
Weighing citric acid, microcrystalline cellulose, soybean phospholipid, isomaltulose, wheat oligopeptide, leucine, β -hydroxy- β -calcium methylbutyrate, glutamine and fish oil microcapsules according to the formula ratio, putting the microcapsules and the second mixture into a three-dimensional mixer, and mixing for 30min at the frequency of 40Hz to form a third mixture.
Weighing the inulin, the collagen peptide, the linseed oil microcapsule powder and the arginine according to the formula ratio, putting the inulin, the collagen peptide, the linseed oil microcapsule powder and the arginine together with the third mixture into a three-dimensional mixer, mixing for 30min at the frequency of 40Hz, and sieving by a 40-mesh sieve to form a fourth mixture.
Weighing the medium-chain triglyceride micro-capsule powder and the separated whey protein according to the formula amount, putting the medium-chain triglyceride micro-capsule powder and the separated whey protein together with the fourth mixture into a pyramid mixer, and mixing for 45min at the rotating speed of 9 rpm.
The dry process of gradient mixing can make various materials fully and uniformly mixed.
(3) Inner bag
Transferring the mixed materials to an inner packaging room for packaging.
(4) Outer bag
And transferring the finished products in the inner bag to an outer bag for packaging.
Test example 1
Effect on the body weight of H22 tumor-bearing mice
Test groups:
test 1 group: cisplatin for injection (20 mg/zhi, manufactured by zilu pharmaceutical co., ltd.).
Test 2 groups: cisplatin for injection (20 mg/ampoule, manufactured by zilu pharmaceuticals, inc.) + EXAMPLE II.
The test method comprises collecting Kunming mouse (male, weight 18-22g), collecting ascites from H22 liver cancer mouse with abdominal passage of 7d under sterile condition, and adjusting cell concentration to 1 × 10 with physiological saline7And/ml. According to the anti-cancer drug research screening protocol, the suspension of H22 tumor cells is inoculated into the subcutaneous area of the right axilla of Kunming mouse, 0.2ml each. H22 after the hepatoma cells are inoculated for 7 days, selecting tumor bodies with the size of 100mm3The left and right mice are divided into a control group, a test 1 group and a test 2 group, the test 1 group is injected with cisplatin 10mg/kg in the abdominal cavity every day, 1 time every day; experiment 2 group is injected with cisplatin 10mg/kg in abdominal cavity every day, and then the two groups of the embodiment are administered with 4.5g/kg by intragastric administration, 1 time every day; the control group is administered with 0.4ml of normal saline for 1 time a day; after 12 days of continuous administration, the mice were weighed and the test results are shown in Table 2.
TABLE 2 Effect of lipopeptide hormones of the invention in combination with cisplatin on the body weight of H22 tumor-bearing mice
Figure BDA0002435990930000091
Note: p <0.01 compared to control group; comparison with trial 1 group # P < 0.05.
And (4) test conclusion: the experiments show that the weight of a mouse is increased after cisplatin treatment, but the weight of the mouse is obviously increased by adding the lipopeptide hormone, and further, the lipopeptide hormone has a good effect on supplementing nutrition for cancer patients.
Test example 2
Clinical preliminary experiments: the lipopeptide obtained in example two can be used for clinical nutrition therapy of malignant tumors.
50 patients with malignant tumors were randomly selected, ranging in age from 30-60 years, with an average age of 48.6 years, of which 23 women and 27 men. When the medicine is eaten, about 150ml of warm water is measured, the first bag of the lipopeptide element in the second embodiment is added, the medicine is drunk after being fully and uniformly stirred, the time is 3 months, and the treatment of other medicines is not stopped within 3 months according to the advice of a doctor. The patient's prealbumin, C-reactive protein, albumin, interleukin-6 related indicators were tested after 3 months, wherein the relevant indicators before and after treatment were shown as follows:
TABLE 3 Change of relevant index before and after treatment of malignant tumor patients
Prealbumin (mg/L) C reactive protein (mg/L) Albumin (g/L) Interleukin-6 (pg/ml)
Before treatment 146±47.31 36±14.86 33±3.24 28±6.81
After treatment 162±64.86 26±20.32 45±4.61 22±4.58
P 0.054 0.028 0.008 0.013
As can be seen from the table, after the lipopeptide element is used for treating malignant tumor patients, the nutritional state of the malignant tumor patients is improved, the albumin and the albumin can be stably improved, the patients can be improved, the immunity is increased, the effect of resisting inflammatory factors is enhanced, various cell factors tend to be balanced in vivo, the disease progress is effectively relieved, and the risk of disease deterioration is reduced.
While the foregoing description shows and describes the preferred embodiments of the present invention, it is to be understood that the invention is not limited to the forms disclosed herein, but is not to be construed as excluding other embodiments and is capable of use in various other combinations, modifications, and environments and is capable of changes within the scope of the inventive concept as described herein, commensurate with the above teachings, or the skill or knowledge of the relevant art. And that modifications and variations may be effected by those skilled in the art without departing from the spirit and scope of the invention as defined by the appended claims.

Claims (15)

1. The lipopeptide element is characterized by comprising the following nutrients in parts by weight:
Figure FDA0002435990920000011
2. the lipopeptide according to claim 1, characterized by comprising the following nutrients in parts by weight:
Figure FDA0002435990920000012
3. the lipopeptide according to claim 1, wherein the protein source is one or more of isolated whey protein, short peptide, amino acid, casein, and sodium caseinate.
4. The lipopeptide peptide of claim 3, wherein the short peptide is one or more of collagen peptide, wheat oligopeptide and sea cucumber peptide.
5. The lipopeptide according to claim 3, wherein the amino acid is one or more of arginine, glutamine and leucine.
6. The lipopeptide according to claim 1 or 2, wherein the fat source is one or more of medium chain triglyceride microcapsule powder, linseed oil microcapsule powder, and fish oil microcapsule.
7. The lipopeptide according to claim 1 or 2, wherein the source of dietary fibre is one or more of resistant dextrin, inulin, isomalto-oligosaccharide, trehalose, oligomannose, microcrystalline cellulose.
8. The lipopeptide according to any one of claims 1 to 7, wherein the raw material source comprises, in parts by weight:
Figure FDA0002435990920000013
Figure FDA0002435990920000021
9. the lipopeptide according to claim 8, further comprising an immunonutrient, wherein the immunonutrient is present in an amount of 1.2-7 parts by weight.
10. The lipopeptide according to claim 9, wherein the source of the immunonutrients is one or more of disodium 5 '-inosinate, disodium 5' -guanylate, soya lecithin, citric acid, zinc gluconate, and shiitake mushroom extract.
11. The lipopeptide according to claim 10, wherein the immunonutrition comprises the following components in parts by weight:
Figure FDA0002435990920000022
12. the lipopeptide according to claim 11, further comprising β -hydroxy- β -methylbutyrate calcium in an amount of 1-3 parts by weight.
13. A production process of lipopeptide is characterized by comprising the following steps:
the method comprises the following steps: weighing 0.02-0.07 part by weight of sucralose, 0.01-0.05 part by weight of disodium 5 '-guanylate, 0.01-0.05 part by weight of disodium 5' -inosinate, 0.08-0.2 part by weight of zinc gluconate, 0.02-0.06 part by weight of vitamin E and 0.15-0.3 part by weight of vitamin C, and uniformly mixing to form a first mixture;
step two: weighing 0.4-0.7 part by weight of oligomannose, 0.2-0.7 part by weight of mushroom extract, 0.3-1 part by weight of sea cucumber peptide, 0.15-0.4 part by weight of bitter taste masking essence and 0.2-0.7 part by weight of milk essence, putting the mixture and the first mixture into a three-dimensional mixer, mixing, and sieving by a 40-mesh sieve to form a second mixture;
weighing 0.5-3 parts by weight of citric acid, 0.5-2 parts by weight of microcrystalline cellulose, 0.5-3 parts by weight of soybean lecithin, 0.5-2 parts by weight of isomaltulose, 0.8-5 parts by weight of wheat oligopeptide, 0.8-5 parts by weight of leucine, 1-3 parts by weight of β -hydroxy- β -calcium methylbutyrate, 0.8-3 parts by weight of glutamine and 1-10 parts by weight of fish oil microcapsule, and putting the mixture and the second mixture into a three-dimensional mixer for mixing to form a third mixture;
step four: weighing 1-9 parts by weight of inulin, 5-9 parts by weight of collagen peptide, 8-20 parts by weight of linseed oil microcapsule powder and 2-6 parts by weight of arginine, putting the inulin and the third mixture together into a three-dimensional mixer, mixing, and sieving by a 40-mesh sieve to form a fourth mixture;
step five: weighing 10-20 parts by weight of medium chain triglyceride microcapsule powder and 20-60 parts by weight of separated whey protein, and mixing the mixture and the fourth mixture in a pyramid mixer to obtain the required lipopeptide.
14. The process for producing lipopeptid according to claim 13, wherein the mixing frequency of the three-dimensional mixer in the second, third and fourth steps is 40Hz, and the mixing time is 30 min.
15. The process for producing lipopeptid according to claim 14, wherein the mixing speed of the square cone mixer in step five is 9rpm, and the mixing time is 45 min.
CN202010252471.7A 2020-04-01 2020-04-01 Lipotide and its production process Active CN111436597B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010252471.7A CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010252471.7A CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Publications (2)

Publication Number Publication Date
CN111436597A true CN111436597A (en) 2020-07-24
CN111436597B CN111436597B (en) 2023-05-12

Family

ID=71649564

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010252471.7A Active CN111436597B (en) 2020-04-01 2020-04-01 Lipotide and its production process

Country Status (1)

Country Link
CN (1) CN111436597B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023015756A1 (en) * 2021-08-10 2023-02-16 河南科谱特医药科技研究院有限公司 Combined functional nutrient for cell absorption
CN116036247A (en) * 2023-02-03 2023-05-02 江中药业股份有限公司 Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846029A (en) * 2018-11-23 2019-06-07 广州欧普康特医食品有限公司 A kind of Elental for cancer patient
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof
CN110892985A (en) * 2019-11-28 2020-03-20 北京诺康达医药科技股份有限公司 Nutritional preparation suitable for perioperative patients

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109846029A (en) * 2018-11-23 2019-06-07 广州欧普康特医食品有限公司 A kind of Elental for cancer patient
CN110892985A (en) * 2019-11-28 2020-03-20 北京诺康达医药科技股份有限公司 Nutritional preparation suitable for perioperative patients
CN110839884A (en) * 2019-12-04 2020-02-28 上海张新生物医药科技有限公司 Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023015756A1 (en) * 2021-08-10 2023-02-16 河南科谱特医药科技研究院有限公司 Combined functional nutrient for cell absorption
CN116036247A (en) * 2023-02-03 2023-05-02 江中药业股份有限公司 Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof
CN116036247B (en) * 2023-02-03 2024-04-05 江中药业股份有限公司 Composition for inhibiting inflammatory response, promoting angiogenesis and wound healing and application thereof

Also Published As

Publication number Publication date
CN111436597B (en) 2023-05-12

Similar Documents

Publication Publication Date Title
CN101223999B (en) Compound for overall supplying various human body-needing nutriments
CN109645320A (en) A kind of light jejunitas full nutrient formulation can brew instant stick and preparation method thereof
CN106174585A (en) Hypoglycemic compositions and hypoglycemic compound probiotic spy&#39;s dietary seafood
CN108991500A (en) A kind of tumour patient full nutrition formula food
CN105876780A (en) Nutritional support of the immune system during anti-cancer treatment
CN112089051A (en) Nutritional composition for improving body inflammatory signs of tumor patients and preparation method thereof
CN111436597A (en) Lipid chain peptide and production process thereof
CN113575934A (en) Total-nutrient compound protein powder for tumor patients
CN110720628A (en) Special clinical nutrition formula for protecting chemotherapy-damaged intestinal mucosa barrier function and preparation method thereof
CN110301629A (en) A kind of full nutrient solid beverage of tumor patient and preparation method thereof
CN104738638A (en) Composition with anti-fatigue effect and application thereof
JP2002535288A (en) Lipoprotein complexes and compositions containing them
CN111493326A (en) Enteral nutrition food and preparation method and application thereof
CN107981339A (en) Tumour full nutrition formula food
CN109090580A (en) A kind of specific full nutritional formulas and preparation method thereof for tumor patient
CN111436601A (en) Special clinical nutrition formula for pancreatic cancer and preparation thereof
CN110150654A (en) A kind of special medicine purposes formula food for tumor patient
CN111802633A (en) Special clinical nutrition formula for esophageal cancer and preparation method thereof
CN108783465A (en) A kind of nutrition formula product with oncotherapy function
CN109007809B (en) Preparation method of special food suitable for intestinal tract of patient with esophageal cancer perioperative period
CN101574145B (en) Nutritional reinforced supplement
CN103082167A (en) Composite enteral nutrition applicable to AIDS patients
CN102228181B (en) Composition eaten by cancer patients and containing oligopeptide and chitosan oligosaccharide
CN114868890A (en) Multi-vitamin nutrient formula suitable for tumor patients
CN115053929A (en) Formula milk powder suitable for people with fatty liver and preparation method thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant